

Eleni-Dimitra Papanagnou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7792560/publications.pdf>

Version: 2024-02-01

28
papers

872
citations

516710

16
h-index

610901

24
g-index

28
all docs

28
docs citations

28
times ranked

1677
citing authors

#	ARTICLE	IF	CITATIONS
1	Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. <i>American Journal of Hematology</i> , 2021, 96, E257-E259.	4.1	138
2	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. <i>Blood</i> , 2021, 137, 3674-3676.	1.4	130
3	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. <i>Blood Cancer Journal</i> , 2021, 11, 138.	6.2	103
4	Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. <i>Blood</i> , 2019, 133, 710-723.	1.4	82
5	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. <i>BMC Medicine</i> , 2021, 19, 208.	5.5	52
6	Nrf2 activation induces mitophagy and reverses Parkin/Pink1 knock down-mediated neuronal and muscle degeneration phenotypes. <i>Cell Death and Disease</i> , 2021, 12, 671.	6.3	38
7	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. <i>Life</i> , 2020, 10, 214.	2.4	31
8	Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 86.	17.0	31
9	Cancer chemoprevention via activation of proteostatic modules. <i>Cancer Letters</i> , 2018, 413, 110-121.	7.2	29
10	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. <i>Blood</i> , 2022, 139, 1409-1412.	1.4	28
11	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021, 11, 1077.	2.4	25
12	The Idirubin Derivative 6-Bromoindirubin-3-Oxime Activates Proteostatic Modules, Reprograms Cellular Bioenergetic Pathways, and Exerts Antiaging Effects. <i>Antioxidants and Redox Signaling</i> , 2017, 27, 1027-1047.	5.4	24
13	Micro-CT for Biological and Biomedical Studies: A Comparison of Imaging Techniques. <i>Journal of Imaging</i> , 2021, 7, 172.	3.0	22
14	Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. <i>British Journal of Haematology</i> , 2022, 196, 356-359.	2.5	18
15	Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. <i>Scientific Reports</i> , 2017, 7, 17802.	3.3	17
16	Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?. <i>American Journal of Hematology</i> , 2021, 96, E321-E324.	4.1	17
17	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. <i>HemaSphere</i> , 2022, 6, e677.	2.7	17
18	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. <i>Leukemia</i> , 2021, 35, 1418-1427.	7.2	15

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. <i>Vaccines</i> , 2021, 9, 207.	4.4	12
20	Osirisynes G-I, New Long-Chain Highly Oxygenated Polyacetylenes from the Mayotte Marine Sponge <i>Haliclona</i> sp.. <i>Marine Drugs</i> , 2020, 18, 350.	4.6	11
21	Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. <i>Oncotarget</i> , 2018, 9, 17797-17809.	1.8	10
22	Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10956.	4.1	8
23	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. <i>HemaSphere</i> , 2021, 5, e614.	2.7	7
24	Chios mastic improves blood pressure haemodynamics in patients with arterial hypertension: Implications for regulation of proteostatic pathways. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 328-331.	1.8	6
25	Isolation of an Extract from the Soft Coral Symbiotic Microorganism <i>Salinispora arenicola</i> Exerting Cytoprotective and Anti-Aging Effects. <i>Current Issues in Molecular Biology</i> , 2022, 44, 14-30.	2.4	1
26	Translating Findings of Proteasome Inhibitors Effects from the in Vivo <i>Drosophila</i> Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib. <i>Blood</i> , 2014, 124, 4814-4814.	1.4	0
27	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. <i>Blood</i> , 2018, 132, 3247-3247.	1.4	0
28	Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging. <i>Blood</i> , 2020, 136, 18-18.	1.4	0